Drug Trial Radar · NCT05041790
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
Last checked: Nov 20, 2026Latest source record: Sep 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
418
Planned (sponsor's estimate)
Start
Sep 30, 2021
Primary completion
Nov 30, 2024
Study completion Nov 30, 2024
Sponsor
- Lead sponsor
- Chong Kun Dang PharmaceuticalIndustry
- Sponsor type
- Industry
- Collaborators
- Choline Alfoscerate Re-evaluation Consortium (57 pharmaceutical companies)
- First posted
- Sep 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, double-blind, placebo-controlled, Phase IV trial to evaluate the efficacy and safety of Choline Alfoscerate compared to placebo in patients with degenerative mild cognitive impairment.
Conditions
- Mild Cognitive Impairment
Interventions
Choline AlfoscerateDrug
Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.
PlaceboDrug
Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of subjects whose cognitive function is maintained/improved at 48 weeks compared to baselineTime frame: Baseline to 48 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Asan Medical Center Institutional Review Board
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.